Assessment of B cell reactivity against MLC1, GlialCAM and EBNA1 in patients with Multiple Sclerosis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035749

Enrollment

162

Registered

2025-03-31

Start date

2025-05-13

Completion date

Unknown

Last updated

2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

G35 G04

Interventions

Group 1: Healthy controls Collection of 10 ml of serum and 40 ml of whole blood Group 2: patients suffering from Multiple sclerosis Collection of 10 ml of serum and 40 ml of whole blood Group 3: patie

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: - Multiple Sclerosis (diagnosis based on meeting the McDonald criteria)

Exclusion criteria

Exclusion criteria: - lack of ability to give informed consent

Design outcomes

Primary

Measure	Time frame
- establishment of an antigen-specific Fluorospot-Assay for MS-related antigens, such as MLC1, GlialCAM and EBNA1 - detection of a potential correlation between the frequency of antigen-specific memory B cells and the severity of the inflammatory neurological disease and MS, respectively.	—

Secondary

Measure	Time frame
- detection of antibodies against MLC1, GlialCAM and EBNA1 in the peripheral blood	—

Countries

Germany

Contacts

Public ContactStefanie Kürtem

Institut für Neuroanatomie, Universitätsklinikum Bonn

stefanie.kuerten@uni-bonn.de+49228732642

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Jun 11, 2026